Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Beam Therapeutics Inc (Beam Therapeutics) is a biotechnology company that primarily focuses on the development of precision genetic medicines using base editing technologies. Its pipeline products include BEAM-101 which treats sickle cell disease; BEAM-103 and BEAM-104 targets sickle cell disease and beta thalassemia; BEAM-302 for alpha-1 antitrypsin deficiency (AATD); and BEAM-301 treats glycogen storage disease 1a (GSD1a). The company primarily serves the healthcare industry, focusing on genetic disorders. Beam Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
238 Main Street, Cambridge, Massachusetts, 02142
Website
beamtx.com
Telephone
1 857 3278775
No of Employees
483
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BEAM (NASD)
Revenue (2024)
$139.7M
120%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
78.8%
(2024 vs 2023)
Market Cap*
$3.6B
Net Profit Margin (2024)
XYZ
90.4%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | RESCUE |
| BEAM-101: | REPAIR |
| Sickle Cell Disease | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In May, the company received a grant from the US Food and Drug Administration for Regenerative Medicine Advanced Therapy designation to BEAM-302, a liver-targeting lipid-nanoparticle formulation to treat patients with alpha-1 antitrypsin deficiency. |
| 2022 | Contracts/Agreements | In January, the company and Beam Therapeutics Inc collaborate to research the rare genetic diseases of the liver, muscle and central nervous system. |
| 2021 | Acquisitions/Mergers/Takeovers | In February, the company announced the acquisition of Guide Therapeutics, a biotechnology company. |
Competitor Comparison
| Key Parameters | Beam Therapeutics Inc | Bristol-Myers Squibb Co | Gilead Sciences Inc | Vertex Pharmaceuticals Inc | Legend Biotech Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | Princeton | Foster City | Boston | Somerset |
| State/Province | Massachusetts | New Jersey | California | Massachusetts | New Jersey |
| No. of Employees | 483 | 32,500 | 17,000 | 6,400 | 2,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Evans | Director; Chief Executive Officer | Executive Board | 2017 | 47 |
| Sravan K. Emany | Chief Financial Officer | Senior Management | 2024 | 47 |
| Manmohan Singh, Ph.D. | Chief Technology Officer | Senior Management | - | - |
| Christine Bellon, Ph.D. | Chief Legal Officer | Senior Management | 2019 | 60 |
| Amy Simon, M.D. | Chief Medical Officer | Senior Management | 2021 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer